Lead Product(s) : Colestipol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
Details : ANI’s Colestipol Hydrochloride Tablets are the generic version of the Reference Listed Drug (RLD) Colestid ®. The current annual U.S. market for Colestipol Hydrochloride Tablets is approximately $81.3 million.
Product Name : Colestipol Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : Colestipol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colestipol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval From USFDA for Colestipol Hydrochloride Tablets
Details : Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.
Product Name : Colestipol Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Colestipol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
